Literature DB >> 21091230

Letter to the Editor: Treatment as prevention: are HIV clinic patients interested in starting antiretroviral therapy to decrease HIV transmission?

Julia C Dombrowski, Robert D Harrington, Mark Fleming, Matthew R Golden.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21091230      PMCID： PMC3011994          DOI： 10.1089/apc.2010.0198

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN： 1087-2914            Impact factor:   5.078


× No keyword cloud information.
  8 in total

1.  Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis.

Authors:  Deborah Donnell; Jared M Baeten; James Kiarie; Katherine K Thomas; Wendy Stevens; Craig R Cohen; James McIntyre; Jairam R Lingappa; Connie Celum
Journal:  Lancet       Date:  2010-05-26       Impact factor: 79.321

2.  Estimating the relative risk in cohort studies and clinical trials of common outcomes.

Authors:  Louise-Anne McNutt; Chuntao Wu; Xiaonan Xue; Jean Paul Hafner
Journal:  Am J Epidemiol       Date:  2003-05-15       Impact factor: 4.897

3.  Universal voluntary testing and treatment for prevention of HIV transmission.

Authors:  Carl W Dieffenbach; Anthony S Fauci
Journal:  JAMA       Date:  2009-06-10       Impact factor: 56.272

4.  Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review.

Authors:  Nicole Crepaz; Trevor A Hart; Gary Marks
Journal:  JAMA       Date:  2004-07-14       Impact factor: 56.272

5.  Ongoing risk behavior among persons with HIV in medical care.

Authors:  Matthew R Golden; Robert W Wood; Susan E Buskin; Mark Fleming; Robert D Harrington
Journal:  AIDS Behav       Date:  2007-05-12

6.  An evaluation of HIV partner counseling and referral services using new disposition codes.

Authors:  Matthew R Golden; Joanne Stekler; James B Kent; James P Hughes; Robert W Wood
Journal:  Sex Transm Dis       Date:  2009-02       Impact factor: 2.830

7.  Effect of early versus deferred antiretroviral therapy for HIV on survival.

Authors:  Mari M Kitahata; Stephen J Gange; Alison G Abraham; Barry Merriman; Michael S Saag; Amy C Justice; Robert S Hogg; Steven G Deeks; Joseph J Eron; John T Brooks; Sean B Rourke; M John Gill; Ronald J Bosch; Jeffrey N Martin; Marina B Klein; Lisa P Jacobson; Benigno Rodriguez; Timothy R Sterling; Gregory D Kirk; Sonia Napravnik; Anita R Rachlis; Liviana M Calzavara; Michael A Horberg; Michael J Silverberg; Kelly A Gebo; James J Goedert; Constance A Benson; Ann C Collier; Stephen E Van Rompaey; Heidi M Crane; Rosemary G McKaig; Bryan Lau; Aimee M Freeman; Richard D Moore
Journal:  N Engl J Med       Date:  2009-04-01       Impact factor: 91.245

Review 8.  Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.

Authors:  Jonathan A C Sterne; Margaret May; Dominique Costagliola; Frank de Wolf; Andrew N Phillips; Ross Harris; Michele Jönsson Funk; Ronald B Geskus; John Gill; François Dabis; Jose M Miró; Amy C Justice; Bruno Ledergerber; Gerd Fätkenheuer; Robert S Hogg; Antonella D'Arminio Monforte; Michael Saag; Colette Smith; Schlomo Staszewski; Matthias Egger; Stephen R Cole
Journal:  Lancet       Date:  2009-04-08       Impact factor: 79.321
  8 in total
  8 in total

1.  Shifting the paradigm: using HIV surveillance data as a foundation for improving HIV care and preventing HIV infection.

Authors:  Patricia Sweeney; Lytt I Gardner; Kate Buchacz; Pamela Morse Garland; Michael J Mugavero; Jeffrey T Bosshart; R Luke Shouse; Jeanne Bertolli
Journal:  Milbank Q       Date:  2013-07-08       Impact factor: 4.911

Review 2.  Clinical uncertainties, health service challenges, and ethical complexities of HIV "test-and-treat": a systematic review.

Authors:  Sonali P Kulkarni; Kavita R Shah; Karthik V Sarma; Anish P Mahajan
Journal:  Am J Public Health       Date:  2013-04-18       Impact factor: 9.308

3.  Clinician Perspectives on Delaying Initiation of Antiretroviral Therapy for Clinically Eligible HIV-Infected Patients.

Authors:  Linda Beer; Eduardo E Valverde; Jerris L Raiford; John Weiser; Becky L White; Jacek Skarbinski
Journal:  J Int Assoc Provid AIDS Care       Date:  2014-11-12

4.  Knowledge, Attitudes, and Acceptability of Pre-Exposure Prophylaxis among Individuals Living with HIV in an Urban HIV Clinic.

Authors:  Jenani Sarah Jayakumaran; Erika Aaron; Ed J Gracely; Emily Schriver; Zsofia Szep
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

5.  Key factors in the acceptability of treatment as prevention (TasP) in Scotland: a qualitative study with communities affected by HIV.

Authors:  I Young; P Flowers; L M McDaid
Journal:  Sex Transm Infect       Date:  2014-12-07       Impact factor: 3.519

Review 6.  How acceptable are antiretrovirals for the prevention of sexually transmitted HIV?: A review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention.

Authors:  Ingrid Young; Lisa McDaid
Journal:  AIDS Behav       Date:  2014-02

7.  Implementation challenges and opportunities for HIV Treatment as Prevention (TasP) among young men in Vancouver, Canada: a qualitative study.

Authors:  Rod Knight; Will Small; Kim Thomson; Mark Gilbert; Jean Shoveller
Journal:  BMC Public Health       Date:  2016-03-15       Impact factor: 3.295

8.  PEP and TasP Awareness among Italian MSM, PLWHA, and High-Risk Heterosexuals and Demographic, Behavioral, and Social Correlates.

Authors:  Gabriele Prati; Bruna Zani; Luca Pietrantoni; Diego Scudiero; Patrizia Perone; Lella Cosmaro; Alessandra Cerioli; Massimo Oldrini
Journal:  PLoS One       Date:  2016-06-13       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.